Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial.

By A. Eggermont, V. Chiarion-Sileni, J. Grob, R. Dummer, J. Wolchok, H. Schmidt, O. Hamid, C. Robert, P. Ascierto, J. Richards and 12 more. The Lancet Oncology, 2015

1,127 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b03c6d9e1293305db329f498f3d6b07976548a1c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. J. Wolchok
2. C. Robert
3. Anand Rotte

In Oncology

1. J. Wolchok
2. C. Robert
3. F. Hodi
4. Anand Rotte
5. M. Postow
6. Antoni Ribas

Citations in the corpus

• Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy (2016, result): “We previously reported the primary results of the EORTC 18071 phase 3 trial in which we compared adjuvant ipilimumab with placebo in patients with resected stage III melanoma.(11) At a median follow-up of 2.”
• Management of toxicities of immune checkpoint inhibitors. (2016, background): “Although rare and occurring in no more than 3% of patients (3% with a 10 mg/kg dose of ipilimumab [4], <1% in other studies [5,8,10,14,16,19,22]), neurological irAEs require prompt recognition and treatment to avoid substantial morbidity.”
• Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. (2019, background): “Therefore, additional trials are mandatory and the respective patient population should be referred to centres offering trial participation [21].”
• Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline (2018, background): “The EORTC 18071 trial reported neurologic irAEs at a rate of 4% in the adjuvant ipilimumab arm.(91) Most neurologic events are mild; headache and peripheral sensory neuropathy are the most commonly encountered symptoms.”